Edzard Schwedhelm

Edzard Schwedhelm is a Professor at the Department of Internal Medicine, affiliated with the Faculty of Medicine at the University of Hamburg, within the Universitätsklinikum Hamburg-Eppendorf (UKE). His research focuses on cardiovascular biomarkers, particularly the roles of arginine metabolism, nitric oxide pathways, and sphingosine-1-phosphate in diseases such as atherosclerosis, heart failure, and ischemic stroke. His work integrates clinical studies with translational research, exploring mechanisms of inflammation, metabolic dysregulation, and their impact on cardiovascular outcomes. Key areas include the predictive value of dimethylarginines in acute conditions like COVID-19 and the interplay between gut microbiota and heart failure progression in animal models. He has contributed to large-scale epidemiological analyses, such as the Study of Health in Pomerania (SHIP), elucidating population-level associations between biomarkers and cardiovascular risk. His studies often involve multicenter collaborations, emphasizing clinical relevance and translational potential.

Publications highlight his expertise in biomarker-driven research, with recent work addressing the implications of S1P and dimethylarginines in thrombosis, platelet function, and arrhythmias. His investigations into exercise interventions in heart failure patients and the effects of pharmacological agents like dapagliflozin reflect his commitment to advancing therapeutic strategies. Ongoing projects explore metabolic pathways in chronic diseases, leveraging metabolomics and genetic models to uncover novel therapeutic targets.